2025
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Callari M, Dugo M, Barreca M, Győrffy B, Galbardi B, Vigano L, Locatelli A, Dall’Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies. Nature Communications 2025, 16: 2195. PMID: 40038334, PMCID: PMC11880565, DOI: 10.1038/s41467-025-57293-9.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesBreast cancerEndocrine therapyImmune infiltrationPrediction of pCRAnti-HER2 therapyLuminal A phenotypeHigher immune infiltrationFemale breast cancerHER2 blockadeDeterminants of responseTumor responseInfiltrating lymphocytesCDK4/6 inhibitionAnti-HER2HER2 targetingClinical endpointsER signalingKi67Response groupCancerTherapyTherapeutic targetMolecular changesTumorPhase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.
Strosberg J, Morris M, Ulaner G, Halperin D, Mehr S, Li D, Soares H, Anthony L, Kotiah S, Jacene H, Tesselaar M, Kunz P, Ferreira D, Li J, Ma K, Rearden J, Moran S, Hope T, Singh S. Phase 1b portion of the ACTION-1 phase 1b/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings. Journal Of Clinical Oncology 2025, 43: 661-661. DOI: 10.1200/jco.2025.43.4_suppl.661.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsPhase 1b portionDose-limiting toxicitySerious adverse eventsGEP-NETsSomatostatin analoguesAdverse eventsFrequent treatment-emergent adverse eventsNo treatment emergent adverse eventsMedian duration of responseTime of data cutoffPlanned dose levelsProgression-free survivalGastroenteropancreatic neuroendocrine tumorsDuration of responseAlpha-emitting radiopharmaceuticalStandard of careDose holdRECIST v1.1Stable diseaseData cutoffDose delaysTumor responseDose modificationPartial response
2024
Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis
Mutonga M, Shewarega A, Gross M, Kahl V, Madoff D. Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis. Clinical Imaging 2024, 115: 110283. PMID: 39278042, DOI: 10.1016/j.clinimag.2024.110283.Peer-Reviewed Original ResearchBeta-blockersTumor responseImaging timepointsTumor sizeEtiology of liver diseaseAssociated with high mortalityTransplant free survivalTransplant-free survivalTreatment of hepatocellular carcinomaFavorable clinical outcomesChild-Pugh scoreFirst-line treatmentBeta-blocker groupPredictors of survivalCox regression analysisTreatment of HCCStudent's t-testFree survivalTransarterial chemoembolizationChi-square testPost-TACETACE treatmentPugh scoreSurvival predictorsAdjunctive use737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
Danska-Bidzinska A, Makker V, Salutari V, Ayhan A, Romero I, Levy T, McCormack M, Baurain J, Mach P, Cadoo K, Mackay H, Friedlander M, Santin A, Slomovitz B, Miller D, McKenzie J, Yao L, Khemka V, Nogueira-Rodrigues A, Marth C. 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study. Annals Of Oncology 2024, 35: s561. DOI: 10.1016/j.annonc.2024.08.799.Peer-Reviewed Original ResearchTumor responseTumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 35: 73-83. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Maldonado E, Rathmell W, Shapiro G, Takebe N, Rodon J, Mahalingam D, Trikalinos N, Kalebasty A, Parikh M, Boerner S, Balido C, Krings G, Burns T, Bergsland E, Munster P, Ashworth A, LoRusso P, Aggarwal R. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Research Communications 2024, 4: 1793-1801. PMID: 38920407, PMCID: PMC11264598, DOI: 10.1158/2767-9764.crc-24-0213.Peer-Reviewed Original ResearchSolid tumor malignanciesStable diseaseTumor malignancyAdverse eventsDepth of tumor responseLoss of H3K36me3Median duration of treatmentAdvanced solid tumor malignanciesClear cell renal cell carcinomaMinor tumor regressionsProlonged stable diseaseArchival tumor tissuePhase II studyCell renal cell carcinomaPhase II trialRenal cell carcinomaDuration of treatmentArchival tissue samplesSimon's two-stageTumor responseTumor regressionII trialMedian durationII studySETD2 mutationsPhase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.
Halperin D, Morris M, Ulaner G, Strosberg J, Mehr S, Li D, Soares H, Anthony L, Kotiah S, Jacene H, Tesselaar M, Kunz P, Ferreira D, Li J, Ma K, Rearden J, Moran S, Hope T, Singh S. Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings. Journal Of Clinical Oncology 2024, 42: 3091-3091. DOI: 10.1200/jco.2024.42.16_suppl.3091.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsPhase Ib portionDose-limiting toxicitySerious adverse eventsGEP-NETsSomatostatin analoguesAdverse eventsFrequent treatment-emergent adverse eventsEfficacy dataData review committeePlanned dose levelsProgression-free survivalDuration of responseGastroenteropancreatic neuroendocrine tumorsLonger-term safetyAlpha-emitting radiopharmaceuticalStandard of careDose holdRECIST v1.1Stable diseasePartial responseStarting doseTumor responseDose modificationNeuroendocrine tumorsAdditive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas
Yadav D, Upadhyay R, Kumar V, Chen M, Johnson J, Langshaw H, Curl B, Farhat M, Talpur W, Beckham T, Yeboa D, Swanson T, Ghia A, Li J, Chung C. Additive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas. Practical Radiation Oncology 2024, 14: e449-e457. PMID: 38685448, DOI: 10.1016/j.prro.2024.04.009.Peer-Reviewed Original ResearchPseudo-progressionResponse assessmentInterobserver agreementImprove response assessmentPost-operative MRIFollow-up MRIFollow-up imagingEvaluate treatment responseHigh-grade gliomasIndependent blinded reviewIdentification of patientsClinical trial enrollmentWeeks of RTPartial response(PRStable disease(SDRT planningSalvage treatmentTumor responseEarly time pointsMedian intervalImprove patient outcomesTrue progressionProspective studyTreatment responseTumor progressionA generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints
Chi X, Yuan Y, Yu Z, Lin R. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical Journal 2024, 66: e2300122. PMID: 38368277, PMCID: PMC11323483, DOI: 10.1002/bimj.202300122.Peer-Reviewed Original ResearchConceptsBayesian hierarchical modeling approachShrinkage parameterTheoretical propertiesPhase II basket trialBasket trialsSimulation studyHierarchical modelHierarchical modeling approachFunctional formGeneral hierarchical modelEfficacy endpointLatent variable approachApproach yieldsRisk-benefit profileVariable approachImmunotherapy agentsTumor responseGeneralizationTargeted therapyCancer subtypesMultiple cancer subtypesTreatment effectsMonitoring procedures
2023
The Predictors of Complete Pathologic Response in Rectal Cancer during the Total Neoadjuvant Therapy Era: A Systematic Review
Flom E, Schultz K, Pantel H, Leeds I. The Predictors of Complete Pathologic Response in Rectal Cancer during the Total Neoadjuvant Therapy Era: A Systematic Review. Cancers 2023, 15: 5853. PMID: 38136397, PMCID: PMC10742121, DOI: 10.3390/cancers15245853.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTotal neoadjuvant therapyPathologic complete responseClinical complete responseNeoadjuvant therapyComplete responseSystematic reviewRectal cancerTumor responseClinical stage 2Complete pathologic responseRetrospective cohort studyRandomized clinical trialsHeterogeneity of studiesLevel of evidenceElectronic databases EmbaseIdentification of predictorsCancer treatment paradigmLong-term trialsNeoadjuvant chemotherapyTherapy eraPatient demographicsPreoperative predictorsClinical factorsClinicopathologic factorsCohort studyIntraprocedural C‐arm dual‐phase cone‐beam enhancement patterns correlate with tumor absorbed dose after radioembolization
Bastiaannet R, Lin M, Frey E, de Jong H. Intraprocedural C‐arm dual‐phase cone‐beam enhancement patterns correlate with tumor absorbed dose after radioembolization. Medical Physics 2023, 51: 3045-3052. PMID: 38064591, PMCID: PMC10994751, DOI: 10.1002/mp.16882.Peer-Reviewed Original ResearchContrast-enhanced cone-beam CTHepatocellular carcinomaPET/CT scansNon-tumor liver tissuesPersonalized treatment planningIntra-procedural imagingBlood flow patternsPretreatment tumorRetrospective studyLimits of agreementTumor responseBland-Altman analysisClinical trialsTumor doseCT scanEnhancement patternHepatic vasculatureHCC tumorsCatheter positionTumor tissueLiver tissueTumorsHepatic radioembolizationPatientsDoseEthiodized oil as an imaging biomarker after conventional transarterial chemoembolization
Mendiratta-Lala M, Aslam A, Bai H, Chapiro J, De Baere T, Miyayama S, Chernyak V, Matsui O, Vilgrain V, Fidelman N. Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization. European Radiology 2023, 34: 3284-3297. PMID: 37930412, PMCID: PMC11126446, DOI: 10.1007/s00330-023-10326-7.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationTreatment response assessmentEthiodized oilHepatocellular carcinomaTransarterial chemoembolizationTreatment responseResponse assessmentIntermediate-stage hepatocellular carcinomaDuration of responsePortion of tumorPost-treatment imagingTissue drug concentrationsPost-treatment prognosisChemotherapy solutionLiver transplantationLocoregional therapyChemotherapy dosesCombination therapyStandard treatmentTherapy optionsTumor responseImaging appearancesIntraarterial embolizationTumor necrosisTumor vasculatureCardiothoracic complications of immune checkpoint inhibitors
Gosangi B, Wang Y, Rubinowitz A, Kwan J, Traube L, Gange C, Bader A. Cardiothoracic complications of immune checkpoint inhibitors. Clinical Imaging 2023, 102: 98-108. PMID: 37659356, DOI: 10.1016/j.clinimag.2023.08.001.Peer-Reviewed Educational MaterialsConceptsImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsOverall survivalTumor responseAdverse effectsDevelopment of irAEsNovel adverse effectsImproved overall survivalOverall patient outcomesICI administrationHematologic malignanciesPatient outcomesSolid tumorsIrAEsCancer treatmentGreater mortalityComplicationsTherapySurvivalInhibitorsMyocarditisPneumonitisPatientsMalignancyImaging the transmembrane pH gradient in gliomas
Mishra S, Mihailović J, Hyder F, Coman D. Imaging the transmembrane pH gradient in gliomas. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/3928.Peer-Reviewed Original ResearchAssess tumor aggressivenessMonitoring treatment efficacyTransmembrane pH gradientTumor responseTumor microenvironmentTumor aggressivenessRG2 tumorsLocal drug deliveryExtracellular acidosisTherapeutic outcomesTumorTreatment efficacyNormal tissuesBrain tumorsIntracellular pHExtracellular pHFunction biomarkersPositive therapeutic outcomesDrug deliveryIntracellular milieuBrainAcidosisGliomaStem-like CD4 T differentiation controls CD8 T cell immunity or tolerance in cancer
Cardenas M, Prokhnevska N, Jansen C, Sobierajska E, Master V, Kissick H. Stem-like CD4 T differentiation controls CD8 T cell immunity or tolerance in cancer. The Journal Of Immunology 2023, 210: 86.04-86.04. DOI: 10.4049/jimmunol.210.supp.86.04.Peer-Reviewed Original ResearchTumor-draining lymph nodesAnti-tumor responsesCD4 T cellsEffector differentiationT cellsT-cell anti-tumor responseTumor-specific CD4 T cellsCD8 T cell responsesCD8 T cell immunityT cell effector differentiationCD4 T cell differentiationReduced tumor burdenT cell responsesT cell immunityDraining lymph nodesT cell differentiationStem-like propertiesExpression of TCF1Tumor responseTumor burdenTreg differentiationLymph nodesCancer responseCD4 differentiationCD8Evolution and implementation of radiographic response criteria in neuro-oncology
Ramakrishnan D, von Reppert M, Krycia M, Sala M, Mueller S, Aneja S, Nabavizadeh A, Galldiks N, Lohmann P, Raji C, Ikuta I, Memon F, Weinberg B, Aboian M. Evolution and implementation of radiographic response criteria in neuro-oncology. Neuro-Oncology Advances 2023, 5: vdad118. PMID: 37860269, PMCID: PMC10584081, DOI: 10.1093/noajnl/vdad118.Peer-Reviewed Original ResearchResponse assessmentClinical trialsNeuro-oncologyNeuro-oncology clinical trialsResponse criteriaRadiographic response assessmentNeuro-Oncology criteriaBrain Tumor ReportingTumor treatment responseAdvanced imaging techniquesRANO criteriaTumor responseTreatment responseClinical practiceSingle tumorTumor compartmentsBidimensional measurementsVolumetric analysisMultiple new approachesTrialsTreatment effectsStandardized approachCurrent research findingsConventional criteriaImaging techniques
2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
Rajdev L, Lee JW, Libutti SK, Benson AB, Fisher GA, Kunz PL, Hendifar AE, Catalano P, O’Dwyer P. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. Investigational New Drugs 2022, 40: 1306-1314. PMID: 36264382, PMCID: PMC9795724, DOI: 10.1007/s10637-022-01311-w.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsTreatment-related grade 3 adverse eventsGrade 3 adverse eventsAdvanced pancreatic neuroendocrine tumorsTwo-stage phase II trialObjective tumor responsePhase II studyPhase II trialContinuous dosing scheduleStage 1Lack of responseEligible patientsMedian OSMedian PFSII trialAdverse eventsII studyObjective responseDosing schedulesTumor responseClinical activityPatientsMTOR pathwayMTORC1/2 inhibitorsThree-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment?
Zhao Y, Haroun R, Sahu S, Schernthaner R, Smolka S, Lin M, Hong K, Georgiades C, Duran R. Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment? Cancers 2022, 14: 3615. PMID: 35892874, PMCID: PMC9329887, DOI: 10.3390/cancers14153615.Peer-Reviewed Original ResearchOverall survivalSecond TACEHepatocellular carcinoma patientsFirst TACECarcinoma patientsTumor responseInitial transarterial chemoembolizationMedian overall survivalTransarterial chemoembolization sessionsKaplan-Meier methodLonger overall survivalLog-rank testChemoembolization sessionsConsecutive patientsTransarterial chemoembolizationSurvival outcomesHCC patientsTreatment responseTumor enhancementPatientsSurvival analysisTACEEuropean AssociationRespondersSignificant differencesA randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).
Kunz P, Graham N, Catalano P, Nimeiri H, Fisher G, Longacre T, Suarez C, Rubin D, Yao J, Kulke M, Hendifar A, Shanks J, Shah M, Zalupski M, Schmulbach E, Reidy D, Strosberg J, Wong T, O'Dwyer P, Benson A. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211). Journal Of Clinical Oncology 2022, 40: 4004-4004. DOI: 10.1200/jco.2022.40.16_suppl.4004.Peer-Reviewed Original ResearchProgression-free survivalPancreatic neuroendocrine tumorsMedian progression-free survivalAdvanced pancreatic neuroendocrine tumorsCombination of capecitabineNeuroendocrine tumorsResponse rateEligible patientsPrimary endpointOverall survivalIntermediate-grade pancreatic neuroendocrine tumorsTwo-sided log-rank testLonger progression-free survivalEfficacy analysis populationObjective tumor responsePhase II trialLog-rank testHigh response rateSecondary endpointsII trialProspective studyAnalysis populationTreatment optionsTumor responseInterim analysisDensity patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057.
Corredor G, Ding R, Prasanna P, Barrera C, Toro P, Viswanathan V, Zens P, Berezowska S, Baxi V, Balli D, Belete M, Velcheti V, Schalper K, Madabhushi A. Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057. Journal Of Clinical Oncology 2022, 40: 2662-2662. DOI: 10.1200/jco.2022.40.16_suppl.2662.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesImmune checkpoint inhibitorsOverall survivalLung adenocarcinomaCheckMate 057Objective responseRisk scoreAnalysis of TILAdvanced-stage lung adenocarcinomaPlatinum-based chemotherapyRisk of progressionCox regression modelDeath risk scoreStage lung adenocarcinomaLung cancer subjectsRECIST v1.1Checkpoint inhibitorsHazard ratioTIL densityPD-L1Better prognosisTumor responseClinical trialsCancer subjectsNivolumab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply